# EDGAR Filing Document

**Accession Number:** 0001389545
**File Stem:** 0001437749-25-036356
**Filing Date:** 2025-11
**Character Count:** 2565
**Document Hash:** 1e3dbeb3e758abfb6bd678bb7a8350f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-036356.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001437749-25-036356

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NovaBay Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001389545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 680454536
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 POWELL STREET, SUITE 1150
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** (510) 899-8800

**MAIL ADDRESS:**
- **STREET 1:** 2000 POWELL STREET, SUITE 1150
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NovaBay Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20070209

**NovaBay Pharmaceuticals, Inc.**

2000 Powell Street, Suite 1150

Emeryville, California 94608

(510) 899-8838

November 25, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| RE: | &nbsp;&nbsp;&nbsp; NovaBay Pharmaceuticals, Inc. |
|  | &nbsp;&nbsp;&nbsp; Registration Statement on Form S-3 (File No. 333-290712) |
|  | &nbsp;&nbsp;&nbsp; Request for Acceleration |

---

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, NovaBay Pharmaceuticals, Inc., a Delaware corporation (the "<u>Company</u>"), hereby respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-290712) (the "<u>Registration Statement</u>") be accelerated by the Securities and Exchange Commission so that it will be declared effective at 4:00 p.m. EST on November 25, 2025, or as soon as possible thereafter. The Company hereby authorizes Timothy Machat of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Timothy Machat of Ropes & Gray LLP at <u>Timothy.Machat@ropesgray.com</u> or (212) 596-9281.

---

| | |
|:---|:---|
| Very truly yours,<br>**NOVABAY PHARMACEUTICALS, INC.** | Very truly yours,<br>**NOVABAY PHARMACEUTICALS, INC.** |
| By: | /s/ Tommy Law |
|  | Tommy Law<br> Chief Financial Officer & Treasurer |

---